Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Castle Biosciences (CSTL) has an analyst price target mean implying 85.2% upside, signaling materially positive Street expectations. The article notes that while price targets alone are imperfect, broad agreement in raising earnings estimates supports an upside view. This is constructive for sentiment, but the piece is commentary rather than a catalyst and is unlikely to drive a large immediate price move.

Analysis

Castle Biosciences (CSTL) has an analyst price target mean implying 85.2% upside, signaling materially positive Street expectations. The article notes that while price targets alone are imperfect, broad agreement in raising earnings estimates supports an upside view. This is constructive for sentiment, but the piece is commentary rather than a catalyst and is unlikely to drive a large immediate price move.